Choreo LLC’s Pacira BioSciences PCRX Stock Holding History

Choreo LLC’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,402	Closed	-$296K	–	1663
2024 Q2	$296K	Buy	+10,402	New	+$296K	0.01%	1103

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Choreo LLC's PCRX Position: Q3 2024 in Review

Choreo LLC sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 10,402 shares — an estimated $296K sold.

Choreo LLC first reported a position in PCRX in Q2 2024 and held it in 1 quarter. The position peaked at $296K in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Choreo LLC reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Choreo LLC sold 10,402 Pacira BioSciences shares in Q3 2024, an estimated $296K.
Choreo LLC first reported a position in Pacira BioSciences in Q2 2024 and held it in 1 quarter.
Choreo LLC's Pacira BioSciences position peaked at $296K in Q2 2024.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Choreo LLC's 13F filing for Q3 2024, filed 7 Nov 2024.